CSIMarket


Galectin Therapeutics Inc   (GALT)
Other Ticker:  
 


 

Galectin Therapeutics Inc

GALT's Financial Statements and Analysis



Galectin Therapeutics Inc increased first quarter of 2024 net loss per share of $-0.19 compare to net loss per share of $-0.19 recorded in the same quarter a year ago a decrease compare to $-0.16 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.19 $  0 Mill
Unch.     Unch.    



Galectin Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Galectin Therapeutics Inc is

More on GALT's Income Statement



Galectin Therapeutics Inc in the first quarter of 2024 recorded net loss of $-11.489 million, an improvement compare to net loss of $-11.527 million in I. Quarter a year ago.

Sequentially net loss advanced

More on GALT's Growth

Galectin Therapeutics Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-2 million


Galectin Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Galectin Therapeutics Inc payed $ -0.55 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -1.18 per share from $ -1.03.

Company issued 1.43 million shares or 2.36 % in Mar 31 2024.


More on GALT's Dividends

 Market Capitalization (Millions) 189
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 11




Galectin Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Galectin Therapeutics Inc had negative $ -0.55 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -1.18 per share from $ -1.03.

Company issued 1.43 million shares or 2.36 % in Mar 31 2024.


More on GALT's Balance Sheets

 Market Capitalization (Millions) 189
 Shares Outstanding (Millions) 62
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 11
   


  News about Galectin Therapeutics Inc Earnings

Galectin Therapeutics Inc Reports Strong First Quarter 2024 Financial Results2.


Date: May 15, 2024
Galectin Therapeutics, Inc. (NASDAQ: GALT), a leading developer of therapeutics targeting galectin proteins, recently announced its financial results and provided a business update for the quarter ended March 31, 2024.
During the earnings season from January to March 2024, investors did not anticipate any significant changes in the company's revenue. However, there was close scrutiny of GALT's operating loss, which amounted to $9.648 million during the same period. It is important to note that the recent management's focus on day-to-day operations has surpassed that of the corresponding three months in the previous year, particularly in the research domain. This finding holds ...

Galectin Therapeutics Inc's Strategic Financial Management Sparks Investor Confidence

The Major Pharmaceutical Preparations sector is buzzing with excitement as insiders analyze the fourth quarter results of 2023. Galectin Therapeutics Inc, a company specializing in therapeutics that target galectin proteins, has reported an operating deficit of $-9.561 million for the October to December 31 quarter of 2023. Although the company has not specified any revenue yet, the progress in managing day-to-day operations has been commendable.
Throughout the fiscal year ending December 31, 2023, Galectin Therapeutics Inc has shown significant improvement in managing their finances. The net deficit per share has widened to $-0.74 from $-0.65 in the previous fiscal year, while the revenue remains unchan...

Galectin Therapeutics Inc Discloses Operating Loss of $9.166 Million in Q3 20232.

Galectin Therapeutics Inc (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, recently announced its financial results and provided a business update for the three months ended on September 30, 2023. According to the Company's Quarterly Report on Form 10-Q, it reported an operating loss of $-9.166 million for that period. Although the revenue has not yet been declared, it is important to analyze the business's performance to gain a better understanding of its current conduct.
During the same quarter in 2022, Galectin Therapeutics Inc recorded an operating loss of $-8.122 million. This suggests that the company has encountered certain challenges in pursuing a successful bu...

The Major Pharmaceutical Preparations Company Causes Investment Stir as Galectin Therapeutics Inc Faces Revenue Setbacks in Q2 2023


Introduction
Galectin Therapeutics Inc is a rapidly growing biotechnology company that specializes in the development and commercialization of novel therapies to treat fibrotic diseases and cancer. In recent years, the company has garnered attention due to its promising pipeline of potential treatments. However, the recent financial statements have shown some moderations in revenue that have caught the shareholders off guard. This article aims to delve into the recent revenue dynamics at Galectin Therapeutics Inc and shed light on how the company is strategizing to overcome these challenges.
Moderations in Revenue: A Change in Expectations
During the fiscal period of April to June 2023, shar...

Galectin Therapeutics Inc Reports $40 Million Net Loss in Q1 2023; Faces Decline in Industry Ranking and Operating Performance

Galectin Therapeutics Inc, a biotechnology company that specializes in developing novel therapies for fibrosis and cancer, recently announced a net loss of $-40 million during 12 month ending in the first quarter 2023. The company is yet to announce revenue for the period, but industry experts have been keeping a close watch on the firm's financial figures.
The Major Pharmaceutical Preparations industry has seen a rise in income per employee across 173 other companies, but Galectin Therapeutics Inc's ranking has dropped from 0 to 2551 in comparison to the forth quarter 2022. Despite this decline, experts anticipate an improvement in...


Date modified: 2024-05-16T00:01:56+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com